Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report

被引：0
|
作者：
Centrone, Renato [1 ]
Bellesso, Marcelo [1 ]
Bonito, Debora [2 ]
Dias, Daniela [1 ]
Santucci, Rodrigo [1 ]
Aranha, Milton [1 ]
Alves, Adelson [1 ]
机构：
[1] Inst Hemomed Oncol & Hematol, Av Arnolfo Azevedo 108, BR-01236030 Sao Paulo, SP, Brazil
[2] Fac Med ABC, Sao Paulo, SP, Brazil
来源：
HEMATOLOGY TRANSFUSION AND CELL THERAPY | 2020年 / 42卷 / 04期
关键词：
DIAGNOSED CHRONIC-PHASE; FOLLOW-UP; THERAPY;
D O I：
10.1016/j.htct.2019.09.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：373 / 375
页数：3
相关论文
共 50 条
  • [21] Comparison of Adherence Between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia
    Guerin, Annie
    Bollu, Vamsi
    Guo, Amy
    Griffin, James D.
    Yu, Andrew Peng
    Wu, Eric Qiong
    BLOOD, 2010, 116 (21) : 1409 - 1409
  • [22] Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase
    Jaideep Gogtay
    Siddharth Chahchad
    Sonali Jadhav
    Shrinivas Purandare
    International Journal of Hematology, 2010, 92 : 772 - 773
  • [23] Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report
    Przespolewski, Eugene R.
    Baron, Jeffrey
    Kashef, Farshid
    Fu, Kai
    Sait, Sheila N. Jani
    Hernandez-Ilizaliturri, Francisco
    Thompson, James
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (02): : 102 - 107
  • [24] Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase
    Gogtay, Jaideep
    Chahchad, Siddharth
    Jadhav, Sonali
    Purandare, Shrinivas
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (05) : 772 - 773
  • [25] A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib
    Smith, B. Douglas
    Liu, Jun
    Latremouille-Viau, Dominick
    Zhou, Zhou
    Guerin, Annie
    Fernandez, Daniel
    Yi, Dingdong
    Wang, Xufei
    Wu, Eric Q.
    Mhatre, Shivani K.
    Keir, Christopher H.
    Chen, Lei
    BLOOD, 2014, 124 (21)
  • [26] Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia
    Yood, Marianne Ulcickas
    Oliveria, Susan A.
    Cziraky, Mark
    Hirji, Ishan
    Hamdan, Muhammad
    Davis, Catherine
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (02) : 213 - 219
  • [27] Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib
    Hornak, Tomas
    Zackova, Daniela
    Mayer, Jiri
    ANNALS OF HEMATOLOGY, 2025, : 2001 - 2004
  • [28] EVALUATION OF THE EFFICACY AND SAFETY OF NILOTINIB 300 BID IN SECOND LINE AFTER IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
    Garcia Gutierrez, V
    Perez Lopez, R.
    Orti, G.
    Casado, F.
    Mora, E.
    Estrada, N.
    Gomez Casares, M.
    Marcos, F.
    Lopez Rodriguez, J. F.
    Ramilla, E.
    Conesa, V
    Piris-Villaespesa, M.
    Sagues, M.
    Cuevas, M., V
    Sanchez Pina, J. M.
    Steegmann, J. L.
    HAEMATOLOGICA, 2019, 104 : 172 - 173
  • [29] PHARMACOECONOMIC EVALUATION OF NILOTINIB VERSUS IMATINIB IN THE FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A SYSTEMATIC REVIEW
    Nguyen, T. T.
    Nguyen, T. T.
    Nguyen, T. B.
    VALUE IN HEALTH, 2017, 20 (05) : A111 - A111
  • [30] Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure
    Al-Ameri, Ali M.
    Cortes, Jorge E.
    Kantarjian, Hagop
    Burton, Elizabeth
    Quintas-Cardama, Alfonso
    Jabbour, Elias
    Badoux, Xavier
    O'Brien, Susan
    Mattiuzzi, Gloria
    BLOOD, 2010, 116 (21) : 527 - 527
12345